Several brokerages have updated their recommendations and price targets on shares of Crispr Therapeutics (NASDAQ: CRSP) in the last few weeks:

  • 12/23/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $84.00 price target on the stock.
  • 12/16/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $104.00 price target on the stock.
  • 12/13/2019 – Crispr Therapeutics was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 12/6/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Wells Fargo & Co.
  • 11/30/2019 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 11/26/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $104.00 price target on the stock.
  • 11/25/2019 – Crispr Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $65.00 to $80.00. They now have an “outperform” rating on the stock.
  • 11/20/2019 – Crispr Therapeutics had its price target raised by analysts at Canaccord Genuity from $72.00 to $80.00. They now have a “positive” rating on the stock.
  • 11/19/2019 – Crispr Therapeutics was upgraded by analysts at William Blair from a “market perform” rating to an “outperform” rating.
  • 11/19/2019 – Crispr Therapeutics had its price target raised by analysts at Goldman Sachs Group Inc from $52.00 to $75.00. They now have a “neutral” rating on the stock.
  • 11/19/2019 – Crispr Therapeutics had its price target raised by analysts at Piper Jaffray Companies from $100.00 to $107.00. They now have a “buy” rating on the stock.
  • 11/19/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Wells Fargo & Co.
  • 11/19/2019 – Crispr Therapeutics had its price target raised by analysts at Roth Capital from $65.00 to $100.00.
  • 11/18/2019 – Crispr Therapeutics had its “buy” rating reaffirmed by analysts at Chardan Capital. They now have a $72.50 price target on the stock.
  • 11/15/2019 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 11/12/2019 – Crispr Therapeutics was upgraded by analysts at Oppenheimer Holdings Inc. from a “market perform” rating to an “outperform” rating. They now have a $65.00 price target on the stock.
  • 11/1/2019 – Crispr Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 10/31/2019 – Crispr Therapeutics was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.
  • 10/28/2019 – Crispr Therapeutics was upgraded by analysts at TheStreet from a “d” rating to a “c” rating.
  • 10/25/2019 – Crispr Therapeutics was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.

NASDAQ CRSP traded up $0.05 during trading hours on Monday, reaching $68.11. 438,079 shares of the company’s stock were exchanged, compared to its average volume of 1,072,989. The firm has a fifty day moving average of $62.13 and a 200-day moving average of $49.47. The stock has a market cap of $3.76 billion, a PE ratio of -19.80 and a beta of 3.30. Crispr Therapeutics AG has a one year low of $22.22 and a one year high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings results on Monday, October 28th. The company reported $2.40 EPS for the quarter, beating the Zacks’ consensus estimate of ($0.95) by $3.35. The firm had revenue of $211.93 million for the quarter, compared to analyst estimates of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%. As a group, research analysts forecast that Crispr Therapeutics AG will post 0.65 EPS for the current year.

In other Crispr Therapeutics news, Director Pablo J. Cagnoni sold 7,500 shares of the business’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the transaction, the director now directly owns 7,500 shares of the company’s stock, valued at $412,500. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, President Rodger Novak sold 33,618 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total value of $2,353,260.00. Following the completion of the transaction, the president now directly owns 33,618 shares of the company’s stock, valued at $2,353,260. The disclosure for this sale can be found here. Insiders have sold 56,118 shares of company stock worth $3,620,760 over the last three months. Corporate insiders own 21.40% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the company. Nikko Asset Management Americas Inc. raised its stake in shares of Crispr Therapeutics by 48.4% during the 3rd quarter. Nikko Asset Management Americas Inc. now owns 2,777,414 shares of the company’s stock worth $113,846,000 after purchasing an additional 906,006 shares during the period. Orbimed Advisors LLC bought a new position in Crispr Therapeutics in the third quarter worth about $21,167,000. Price T Rowe Associates Inc. MD lifted its holdings in shares of Crispr Therapeutics by 19.6% during the second quarter. Price T Rowe Associates Inc. MD now owns 738,869 shares of the company’s stock valued at $34,801,000 after purchasing an additional 121,176 shares during the last quarter. Wells Fargo & Company MN raised its position in Crispr Therapeutics by 23.9% in the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after buying an additional 116,540 shares during the last quarter. Finally, Balyasny Asset Management LLC purchased a new stake in Crispr Therapeutics in the 2nd quarter worth approximately $5,165,000. 49.82% of the stock is currently owned by institutional investors.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Further Reading: Real Estate Investment Trust (REIT) ETF



Receive News & Ratings for Crispr Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.



Source link